Bagchi, Soumita published the artcileSignificance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study, Application of (2R,3S,4S,5R)-2,3,4,5,6-Pentahydroxyhexanal, the main research area is IgA1 serum galactose IgA nephropathy.
Background: IgA nephropathy(IgAN) is a common glomerular disease with a higher risk of progression to end stage renal disease (ESRD) in certain ethnic populations. Since galactose deficient IgA1(Gd-IgA1) is a critical mol. in its pathogenesis, it has generated interest as a biomarker for this disease. Methods: We measured serum Gd-IgA1 levels using a non- lectin based enzyme linked immunoassay (ELISA) in 136 immunosuppression naive patients with primary IgAN and 110 controls(60-non IgA glomerular diseases, 50-healthy volunteers). Results: Median serum Gd-IgA1 levels were significantly higher in IgAN patients [13135.6(2723.3,59603.8)ng/mL] compared to those with non IgA glomerular disease [4954.8(892.9,18256.2) ng/mL] and healthy controls [6299.5(1993.2,19256) ng/mL] and this was observed even after log transformation and adjustment for age and gender(p<0.0001). Considering a cut-off value of serum Gd-IGA1 â?7982.1ng/mL, the sensitivity for diagnosing IgAN compared to healthy controls was 74.3% and specificity was 72.0% with a pos. predictive value of 87.8% and neg. predictive value of 50.7%. The serum Gd-IgA1 level did not co-relate with baseline estimated glomerular filtration rate, urine protein creatinine ratio and the M, E, S, T and C scores on renal biopsy. The renal survival (absence of >30% decrease in eGFR, ESRD or death) was lower in patients with higher serum Gd-IgA1 levels(â?982ng/mL) than those who had lower levels but it was not statistically significant(p = 0.486). Conclusion: Serum Gd-IgA1 level is higher in IgAN patients compared to non-IgA glomerular diseases and healthy controls and has a good pos. predictive value for diagnosis. However, it does not correlate with clin. and histol. characteristics of disease severity and does not predict disease progression.
PLoS One published new progress about Biomarkers. 59-23-4 belongs to class alcohols-buliding-blocks, name is (2R,3S,4S,5R)-2,3,4,5,6-Pentahydroxyhexanal, and the molecular formula is C6H12O6, Application of (2R,3S,4S,5R)-2,3,4,5,6-Pentahydroxyhexanal.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts